Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non-Hodgkin lymphomas: A phase IB/II study
- PMID: 34731510
- DOI: 10.1002/ajh.26400
Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non-Hodgkin lymphomas: A phase IB/II study
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources